Smithkline Beecham Corporation

Smithkline Beckman Corporation

Smithkline Corporation

James S Frazee

Carl Kaiser

Lawrence I Kruse

John G Gleason

Scott Kevin Thompson

Lara Kallander

Michael J Neeb

Chun Ma

Ajita Bhat

Siegfried B Christensen, Iv

Ralph F Hall

Joseph Marino

Joseph M Karpinski

Jack Dale Leber

Stephen T Ross

Brian W Metcalf

Russell Donovan Cousins

Joseph A Finkelstein

Joseph P Marino, Jr

Thomas B Leonard

Mei Li

Robert A Stavenger

Timothy Yu-Wen Jen

Martha S Head

Pamela A Chambers

John Jeffrey McAtee

Ning Wang

Disclosed is a compound having the formula: 

Compounds and methods

Disclosed is a compound of having the formula: 

Disclosed is a compound having the formula (I) pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists 

Amide compounds and methods of using the same

PDF inhibitors and novel methods for their use are provided.

Peptide deformylase inhibitors

Substituted-pent-4-ynoic acids

Cytokine inhibiting imidazole substituted hydroxamic acid derivatives

This invention relates to alkanoic acid compounds having phenyl and heteroarylthio substituents which are useful as leukotriene antagonists, processes for the preparation thereof, and pharmaceutical compositions containing such compounds. This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

Leukotriene antagonists

This invention relates to (R)-.alpha.-methyl-4-halobenzenemethanamine salts of epimers of acids of the formula ##STR1## and the use of these salts to separate these epimers. These acids are leukotriene antagonists.

This invention covers quinolinyl substituted phenyl/thioalkanoic acid substituted propionic acids leukotriene inhibitors having the following general formula ##STR1## where the substituents are defined herein.

Quinolinyl substituted phenyl/thioalkanoic acid substituted propionic

Potent DBH inhibitors having the formula ##STR1## can be used to inhibit DBH activity in mammals.

Dopamine-.beta.-hydroxylase inhibitors

Potent DBH Inhibitors having the formula: ##STR1## wherein R is --CO.sub.2 H or --CH.sub.2 NHR.sup.1 can be used to inhibit DBH activity in mammals.

Dopamine .beta.-hydroxylase inhibitors

Potent, irreversible dopamine-.beta.-hydroxylase inhibitors having the Formula: ##STR1## which are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors or 2-cyano-2-phenethylamine, and methods of using these inhibitors or 2-cyano-2-phenethylamine to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.

Irreversible dopamine-.beta.-hydroxylase inhibitors

Compounds having the formula: ##STR1## which are ester prodrugs of potent dopamine-.beta.-hydroxylase inhibitors and thus are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmeceutical compositions including these compounds, and methods of using these compounds to inhibit dopamine-.beta.-hydroxylase activity in mammals.

Ester prodrugs of dopamine-.beta.-hydroxylase, inhibitors, composition

Potent DBH inhibitors having the formula: ##STR1## wherein R is --CO.sub.2 H or --CH.sub.2 NHR.sup.1 can be used to inhibit DBH activity in mammals.

Growing community of inventors

Sewell, NJ, United States of America

James S Frazee